Clinical effect of Fumarate Vorolasan Tablets combined with Lansoprazole in the treatment of gastroesopha-geal reflux pharyngo-laryngeal disease
ZHENG Yi1 WANG Wenbin2 SHAN Chunyan3#br#
1.Department of Otolaryngology, Suzhou Ninth People’s Hospital, Jiangsu Province, Suzhou 215200, China;
2.Department of Otolaryngology, Suzhou Municipal Hospital, Jiangsu Province, Suzhou 215200, China;
3.Department of Otolaryngology, Suzhou City Wujiang Hospital of Traditional Chinese Medicine, Jiangsu Province, Suzhou 215200, China
Abstract：Objective To explore the clinical efficacy of Fumarate Vorolasan Tablets combined with Lansoprazole in the treatment of gastroesopha-geal reflux pharyngo-laryngeal disease. Methods A total of 82 patients with gastroesopha-geal reflux pharyngo-laryngeal disease admitted to Suzhou Ninth People’s Hospital, Jiangsu Province from January 2020 to November 2021 were selected as the research objects. They were divided into study group and control group by computer random number method, with 41 cases in each group. The control group was treated with Lansoprazole, and the study group was treated with Fumarate Vorolasan Tablets combined with Lansoprazole. The clinical efficacy, symptoms of laryngopharyngeal reflux, gastrointestinal hormones, and serum inflammatory factors were evaluated at 28 days after administration, and the incidence of adverse reactions in both groups was recorded. Results The clinical effect of the study group was better than that of the control group (P ＜ 0.05). After treatment, the reflux disease questionnaire (RDQ) score, gastrointestinal impact scale (GIS) score, and the levels of tumor necrosis factor -α (TNF-α), interleukin-1β (IL-1β), and vasoactive intestinal peptide in two groups were lower than those before treatment, and gastrin level was higher than before treatment (P ＜ 0.05). After treatment, RDQ, GIS score, and levels of TNF-α, IL-1β, and vasoactive intestinal peptide in the study group were lower than those in the control group, while gastrin level was higher than that in the control group (P ＜ 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Fumarate Vorolasan Tablets combined with Lansoprazole in the treatment of gastroesopha-geal reflux pharyngo-laryngeal disease patients, which has superior clinical efficacy and good safety, worthy of promotion.
京公网安备 11010502046598号